Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 2/20 | 0.61 |
| ▸ | CA2 | P00918 | 2/20 | 0.61 |
| ▸ | CA4 | P22748 | 2/20 | 0.61 |
| ▸ | CA9 | Q16790 | 2/20 | 0.61 |
| ▸ | REN | P00797 | 2/20 | 0.50 |
| ▸ | SLC6A4 | P31645 | 4/20 | 0.49 |
| ▸ | SLC6A3 | Q01959 | 4/20 | 0.49 |
| ▸ | SLC6A2 | P23975 | 3/20 | 0.49 |
| ▸ | DPP4 | P27487 | 4/20 | 0.48 |
| ▸ | DPP7 | Q9UHL4 | 2/20 | 0.47 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.46 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | MITF | O75030 | 1/20 | 0.44 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4283232 | 1.00 | CA1 (0.61) | CA1CA2CA4CA9REN | |
| SCHEMBL4283432 | 0.90 | CA1 (0.56) | CA1CA2CA4CA9REN | |
| SCHEMBL4283441 | 0.90 | CA1 (0.56) | CA1CA2CA4CA9REN | |
| SCHEMBL4288010 | 0.86 | CA1 (0.58) | CA1CA2CA4CA9REN | |
| SCHEMBL4288007 | 0.86 | CA1 (0.58) | CA1CA2CA4CA9REN | |
| SCHEMBL4281205 | 0.83 | CA1 (0.58) | CA1CA2CA4CA9REN | |
| SCHEMBL4281201 | 0.83 | CA1 (0.58) | CA1CA2CA4CA9REN | |
| SCHEMBL27563025 | 0.82 | CA1 (0.57) | CA1CA2CA4CA9REN | |
| SCHEMBL27563026 | 0.82 | CA1 (0.57) | CA1CA2CA4CA9REN | |
| SCHEMBL590923 | 0.81 | CA1 (0.62) | CA1CA2CA4CA9REN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090105251-A1 | Renin inhibitors | TAKEDA SAN DIEGO, INC. | 2009-04-23 | — | — | US | claimed |
| US-20090105251-A1 | Renin inhibitors | TAKEDA SAN DIEGO, INC. | 2009-04-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090105251-A1 | Renin inhibitors | REN, ACE, AGT | CA1 1185/4885CA2 275/4885CA4 379/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.